Adverse event reports for food, drugs, vaccines, dietary supplements and medical devices will soon be available in one place. The U.S. Food and Drug Administration said the change will simplify reporting for consumers and allow it to react in real-time to FOIA requests.

Many of the details are unknown, as an investigation is ongoing. The National Association on Drug Abuse Programs said it became aware of an invasion of its network in January 2026. The nonprofit supports 35,000 people—mainly Medicaid enrollees—in the state of New York. 

Stryker, a Michigan-based company that manufactures surgical implants, confirmed it was experiencing a global network outage. Employee devices reportedly displayed the logo of a pro-Iran cybercrime cell.

The U.S. Department of Justice said the insurer upcoded patient diagnoses to boost risk-adjusted payments it received from the Centers for Medicare & Medicaid Services. The company did not admit to wrongdoing, despite agreeing to the payout. 

The devices are manufactured by Erbe USA. They’re used to deliver pressurized cold therapy to tumors, blood clots, and more. A manufacturing defect can cause a rupture, exposing anyone in the vicinity to a dangerous blast and deafening sound.

The company confirmed the number of victims in filings with the federal government and the state of Maine. The data breach was discovered in October 2025, but it began in November 2024. Hackers were siphoning protected health information for roughly a year.

The Medical Group Management Association explains some positive federal healthcare policy movement since the start of 2026, including extending telehealth and rural health payments, and possible solutions to the prior authorization burden in Medicare Advantage.   

The dispute centered around the pharmaceutical company's request for the shot to be approved for those aged 65 and over, a demographic the FDA argued was not properly represented in a 40,000-person clinical study. The company has agreed to perform additional research after the shot goes to market, having appeased regulators with safety data.

A U.S. District Court in Texas ruled that the agency overstepped its regulatory authority in passing the 2024 Biden-era reporting requirement, which would require stakeholders to spend more than 100 hours filling out a long form to give the agency more oversight of transactions. 

The randomized COBRRA trial included more than 2,700 patients with acute symptomatic pulmonary embolism or proximal deep-vein thrombosis. 

Meanwhile, docs have helped defeat the controversial policy's implementation in Indiana with the passage of Senate Bill 189.